BioXcel Therapeutics, Inc.
BTAI
$1.85
$0.169.47%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 2.27M | 2.28M | 2.40M | 1.76M | 1.38M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.27M | 2.28M | 2.40M | 1.76M | 1.38M |
| Cost of Revenue | 2.14M | 2.03M | 1.37M | 1.33M | 1.26M |
| Gross Profit | 122.00K | 250.00K | 1.04M | 424.00K | 119.00K |
| SG&A Expenses | 34.49M | 40.00M | 56.66M | 73.08M | 83.41M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 67.07M | 76.49M | 107.02M | 142.34M | 169.00M |
| Operating Income | -64.80M | -74.22M | -104.61M | -140.59M | -167.62M |
| Income Before Tax | -59.60M | -71.00M | -107.83M | -153.05M | -179.05M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -59.60 | -71.00 | -107.83 | -153.05 | -179.05 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -59.60M | -71.00M | -107.83M | -153.05M | -179.05M |
| EBIT | -64.80M | -74.22M | -104.61M | -140.59M | -167.62M |
| EBITDA | -64.50M | -73.91M | -104.30M | -140.27M | -167.30M |
| EPS Basic | -25.91 | -34.43 | -56.88 | -82.91 | -98.55 |
| Normalized Basic EPS | -15.61 | -20.94 | -33.91 | -50.40 | -60.17 |
| EPS Diluted | -25.91 | -34.43 | -56.88 | -82.91 | -98.55 |
| Normalized Diluted EPS | -15.61 | -20.94 | -33.91 | -50.40 | -60.17 |
| Average Basic Shares Outstanding | 10.13M | 8.94M | 8.12M | 7.42M | 7.28M |
| Average Diluted Shares Outstanding | 10.13M | 8.94M | 8.12M | 7.42M | 7.28M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |